- On Sept. 2, the U.S. Food and Drug Administration (FDA) approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting. Read more.
- On Aug. 27, the FDA approved Repatha (evolocumab) injection for some patients who are unable to control their low-density lipoprotein (LDL) cholesterol with current treatment options. Read more.
FDA approves new drugs
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
